CHF 5993 HFA-152a inhaled formulation (pMDI)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CHF 5993 HFA-152a inhaled formulation (pMDI), covering 2026-04-23 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists [Phase 3]